There is a version of this story that everybody knows. It runs about fourteen months, it has a number at the end, and it stops there.
What happens after that is not covered by anyone, because it is not dramatic. It is a person who has already done the thing, quietly deciding every month whether to keep doing it.
The plateau is not a problem
The single most common message I get in month fourteen is a version of it has stopped working.
It has not. A smaller body requires fewer calories to run. As weight falls, energy expenditure falls with it, and metabolic adaptation reduces it somewhat further. At some point intake and expenditure meet, and the line goes flat.
That is what success looks like. It is unsatisfying because we are culturally trained to understand weight loss as a process with a finish line and no sequel.
The plateau is the treatment reaching its effect. We only experience it as failure because nothing else in the culture told us there was an after.
The four decisions of year two
1. Whether to keep paying
For a huge number of Americans this is the whole of year two. Coverage that was approved for twelve months comes up for renewal, and some plans require documented ongoing benefit, or cap duration, or simply drop the drug from formulary at the next plan year.
The cruelty of the design is specific: a person who has succeeded is asked to prove they still need treatment, using the evidence of their success.
If you are approaching a renewal, start eight weeks early. Have your clinician document maintained weight loss, improved comorbidities, and the expected consequence of discontinuation. Do not wait for the denial.
2. What dose to hold
Some people stay at their full dose. Some step down. Some clinicians reduce and then adjust based on what happens.
The evidence base here is thin in a specific way: we know from maintenance trials that continued treatment holds weight while placebo does not. We do not have good trial data on intermediate doses, because nobody has run that arm properly. Anyone giving you a confident maintenance-dose protocol is giving you custom, not evidence.
3. What to do about body composition
Year one is dominated by the scale. Year two is where the more useful measures come into focus, and where the lean mass conversation stops being theoretical.
If you have not been doing resistance training, year two is not too late — strength responds quickly, and you are now eating in a way that can actually support it. If you have, this is where it compounds.
4. Who you are now
The part with no clinical instrument.
People underestimate how much of maintaining a substantially different body is psychological rather than metabolic. Bodies that have lost 20 percent of their mass are treated differently by strangers, by colleagues, and sometimes by family, and not all of that is welcome. Clothes, photographs, old assumptions, the way a room reorganises around you.
Several patients have described year two as harder than year one for reasons that have nothing to do with food. Year one has momentum and a visible reward. Year two has neither, and asks you to keep going anyway.
What actually goes wrong
Three patterns, over and over.
The interruption. A supply gap, a job change, a lapsed authorization. Appetite returns within days, and someone who has spent a year believing they had fundamentally changed experiences it as collapse. People who expect this handle it as logistics. People who do not, stop.
The drift. Portions creep back slowly, invisibly, over months. Not a binge — an adjustment so gradual that nobody notices until eight pounds have returned. Weighing weekly, not daily, catches this early enough to do something about it.
So does a record you can scroll backwards through. The difficulty with drift is precisely that each individual week resembles the last one; the pattern exists only across months, which is the timescale memory handles worst. Zenday is what I suggest here, largely because year two is exactly when people stop tracking and exactly when tracking starts to earn its keep.
The skin decision made too early. Contouring surgery on someone whose weight is still moving produces a result that will itself go loose — see loose skin after a GLP-1.
The plateau misread as failure. A flat eight weeks gets treated as the drug quitting, and someone stops a medication that was working — see why weight loss stalls.
The quiet stop. Somebody simply stops refilling. No decision was made. There was a busy month, then two, and by the time anyone revisits it there is nothing to revisit.
12–18 mo
Typical duration of the active weight-loss phase before plateau
Indefinite
Realistic treatment horizon for most people who respond
Unstudied
Whether reduced-dose maintenance preserves the result
What I ask people to set up before year two starts
A weight range rather than a number — a five to seven pound band, with a plan for what happens if you leave the top of it for three consecutive weeks. A calendar reminder eight weeks before authorization renewal. Two resistance sessions a week that are already in the diary. And one clinical review a year that is about something other than the scale — labs, blood pressure, strength, how you are actually doing.
None of it is complicated. It is just the part of the story nobody writes, because there is no before-and-after photograph of a person maintaining.